The effect of glycoprotein IIIa PIA1/A2 polymorphism on the PFA-100 response to GP IIbIIIa receptor inhibitors - The importance of anticoagulants used

Journal of Thrombosis and Thrombolysis

Volumn 20, Issue 1, 2005, Pages 57-63

  Aalto Setälä, Katriina ^a   Karhunen, Pekka J ^a,b   Mikkelsson, Jussi ^a,b   Niemelä, Kari ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

GP IIbIIIa receptor; GP receptor inhibitors; PFA 100; PIA polymorphism

Indexed keywords

ABCIXIMAB; ADRENALIN; CALCIUM; CITRATE SODIUM; COLLAGEN; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IIIA; TIROFIBAN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADULT; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; EXONS; FEMALE; GENOTYPE; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOLYTIC THERAPY;

EID: 24944555873     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-2912-2     Document Type: Article

References (34)

1. Becher RC. Thrombosis and the role of the platelet. Am J Cardiol 1999;83:3E-6E. 10.1016/S0002-9149(99)00083-1
2. Kamath S, Blann AD, Lip GYH. Platelet activation: Assessment and quantification. Eur Heart J 2001;22:1561-1571. 10.1053/euhj.2000.2515
3. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. 1995;332:1553-1559.
4. Bednar RA, Gaul SL, Hamill TG, et al. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. J Pharmacol Exp Ther 1998;285:1317-1326. 9618439
5. Tcheng JE. Differences among the parenteral platelet glycoprotein IIb/ IIIa inhibitors and implications for treatment. Am J Cardiol 1999;83:7E-11E. 10.1016/S0002-9149(99)00084-3
6. Dickfeld T, Ruf A, Pogatsa-Murray G, et al. Differential antiplatelet effects of various glycoprotein IIbIIIa antagonists. Thrombosis Research 2001;101:53-64. 10.1016/S0049-3848(00)00385-6
7. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999 Nov 16;100(20):2045-2048.
8. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001 Jun 21;344(25):1879-1887. 10.1056/NEJM200106213442501
9. Wu KK, Willerson JT. Monitoring platelet function in glycoprotein IIB/ IIIA inhibitor therapy (editorial). Circulation 2001 May 29;103(21):2528-2530.
10. Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoprotein IIbIIIa inhibitors. J Interv Cardiol 2002;15:45-60. 12053684
11. Nurden AT, Poujol C, Durrie-Jais C, Nurden P. Platelet glycoprotein IIb/ IIIa inhibitors: Basic and clinical aspects. Arterioscler Thromb Vasc Biol 1999;19:2835-2840. 10591658
12. Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999;84:203-207. 10.1016/ S0002-9149(99)00235-0
13. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PIA1 and PIA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:1778-1781. 2565345
14. Beer JH, Pederiva S, Pontiggia L. Genetics of platelet receptor single-nucleotide polymorphisms: Clinical implications in thrombosis. Ann Med 2000;32 Suppl 1:10-15. 11209974
15. Williams MS, Bray PF. Genetics of arterial prothrombotic risk states. Exp Biol Med 2001;226:409-419.
16. Burr D, Doss H, Glen EC, Goldschmidt-Clrmont PJ. A meta-analysis of studies on the association of the platelet PIA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Statist Med 2003;22:1741-1760. 10.1002/sim.1375
17. Mikkelsson J, Perola M, Laippala P, et al. Glycoprotein IIIa Pl(A) Polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol 1999;19:2573-2578. 10521390
18. Mammen EF, Comp PC, Gosselin R, et al. PFA-100™ system: A new method for assessment of platelet dysfunction.
19. Kekomäki S, Partanen J, Kekomäki R. Platelet alloantigens HPA-1, -2,-3, -5 and -6b in Finns. Transfus Med 1995;3:193-198.
20. Marciniak SJ, Jordan RE, Mascelli MA. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost 2001;85:539-543. 11307828
21. 3. J Biol Chem 2000;276:7795-7802. 10.1074/jbc.275.11.7795
22. Plow EF, Ginsberg MH. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Progress in Hemostasis and Thrombosis 1989;9:117-156 2643815
23. Kereiakes DJ, Lorenz T, Young JJ, et al. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thrombosis Thrombolysis 2001;12:123-127. 10.1023/A:1012991303381
24. Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies. Discriminating abciximab and small molecular weight antagonists. Circulation 1999;99:2231-2238. 10226086
25. Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 2000;84:1095-1102. 11154119
26. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca sup 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-1494. 9315536
27. 2+ -dependent binding of a synthetic arg-gly-asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb-IIIa complex. J Biol Chem 1989;264:13102-13108. 2753902
28. O'Connor FF, Shields DS, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001;98:3256-3260. 10.1182/blood.V98.12.3256
29. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa P1 A polymorphisms display different sensitivities to agonists. Circulation 2000;101:1013-1018. 10704169
30. Wheeler GÖ, Braden GA, Bray PF, Marciniak SJ, Marcelli MA, Sane DC. Reduced inhibition by abciximab in platelets with the PIA2 polymorphism. Am Heart J 2002;143:76-82. 10.1067/mhj.2002.119763
31. Rozalski M, Watala C. Antagonists of platelet fibrinogen receptor are less effective in carriers of PI(A2) polymorphism of beta(3) integrin. Eur J Pharmacol 2002;454:1-8. 10.1016/S0014-2999(02)02391-9
32. Weber A-A, Jacobs C, Meila D, et al. No evidence for the influence of the human platelet antigen 1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics 2002;12:581-583. 10.1097/00008571-200210000-00011
33. Williams MS, Bray PF. Genetics of arterial prothrombotic risk states. Exp Biol Med 2001;226:409-419.
34. Loftus JC, Smith JW, Ginsberg MH. Integrin-mediated cell adhesion: The extracellular face. J Biol Chem 1994;269:25235-25238. 7929213